ASX ANNOUNCEMENT

Actinogen to present at ShareCafe Small Cap Webinar

Sydney, 4 August 2021. Actinogen Medical ASX: ACW ('Actinogen' or 'the Company') is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 6th of August 2021 from 12:30pm AEST / 10:30am AWST.

Actinogen CEO and Managing Director Dr. Steven Gourlay will provide an overview of the Company's novel therapy for neurological diseases associated with dysregulated brain cortisol, the once daily oral medication Xanamem™, a promising new therapy for Alzheimer's Disease, Fragile X syndrome, and other neurological diseases.

This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

https://us02web.zoom.us/webinar/register/5416151767246/WN_PZu7bDw3T6elbu04A5cUwA

A recorded copy of the webinar will be made available following the event.

A copy of the investor presentation to be delivered during the webinar is attached.

ENDS

Actinogen Medical

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E: steven.gourlay@actinogen.com.au

Investor Enquiries

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. 'Cognition' relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

Actinogen Medical's lead drug candidate, **Xanamem®,** has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in **Alzheimer's Disease**, potentially linked to cognitive impairment and anxiety in **Fragile X syndrome**, and cognitive impairment in neuropsychiatric diseases.

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases.

In the Company's recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company plans to initiate a range of Phase II studies evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer's disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a registered trademark of Actinogen Medical.

Disclaimer
This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

ShareCafe Presentation

Dr. Steven Gourlay: CEO & Managing Director

6 August 2021

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. ("Actinogen" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is **NO guarantee of future performance**. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (**Parties**) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

Actinogen snapshot

Actinogen Medical (ASX:ACW) is a public company developing Xanamem®; a novel small molecule for cognitive impairment

Favourable drug	Substantial Clinical Data	Attractive targets	Protected & Funded
✓ **Brain penetrant**, 11β-HSD1 enzyme **(cortisol) inhibitor** ✓ **Favourable pharmaceutic properties** ✓ **Safe** and well tolerated	✓ **>200 subjects** treated ✓ Significant preclinical and clinical **data generated** ✓ **Sub-analysis** completed	✓ **Significant opportunity** in Mild Cognitive Impairment due to Alzheimer's disease ✓ **Strategic benefits** from Fragile X syndrome[1]	✓ **Comprehensive patents** in place[2] ✓ **Strong cash balance** with ~$13.46M in cash as at 30 June 2021

Actinogen is well placed to fully fund its Phase 2 clinical trials and expand the clinical pipeline

Actinogen Medical

1. Rare Paediatric Disease Designation (RPDD) granted by the U.S. Food and Drug Administration (FDA)
2. Composition of matter to 2031 plus 5-year extension in most countries

Corporate overview

Major shareholders remain supportive through share price appreciation

Major Shareholders

BVF Partners	**14.4%**
Steven Gourlay[1]	3.8%
Edinburgh Technology Fund	2.9%



Financial Information

52 week high	**A$0.195**
52 week low	A$0.019
Share price (28 July 2021)	A$0.110
Number of shares	1,660.6M
Market capitalisation (28 July 2021)	A$182.7M
Net cash[2]	A$13.46M

Experienced Board & Senior Management

Dr. Geoff Brooke
Chairman
MBBS; MBA

Dr. George Morstyn
Non-Executive Director
MBBS; PhD; FRACP; MAICD

Mr. Malcolm McComas
Non-Executive Director
BEc, LLB; FAICD; SF Fin

Dr. Steven Gourlay
CEO & MD
MBBS; FRACP; PhD; MBA

Jeff Carter
Chief Financial Officer
B. Fin Admin; M. App. Fin; CA

Tamara Miller
Vice President Drug Development & Strategy
M.Med; M.PharmSci; BSc; MSc; PMP; CPPM

Share Price Performance[3]



Source: IRESS
1. Holding based on loan plan shares (~48M), and shares acquired in the 2021 shortfall placement (~15M)
2. Cash as at 30 June 2021
3. Volume traded on 5 Feb 2021 of 283.1M has been capped due to differences in volume.

Actinogen Medical

Xanamem – small molecule drug with a novel mechanism of action

Xanamem is a brain[1] penetrant 11ß-HSD1 small molecule enzyme inhibitor; designed to inhibit excessive cortisol production in the brain



1. Xanamem is a CNS (Central Nervous System) penetrant small molecule

Clinical pipeline for Xanamem

Major clinical trials targeting brain penetration, improved cognition and other benefits

Planned studies	Pathway (illustrative)	*Outlook*
Mild cognitive impairment due to **Alzheimer's disease**	**XanaMIA - *Commenced*** **Part A:** 10mg, 5mg, Placebo **Part B:** MCI due to AD, biomarkers	*Potential to address all stages of the disease*
Anxiety, sleep & behavioural problems in **Fragile X syndrome**	FDA Pre-IND Meeting → **XanaFX – *Commence 2H CY21*** Phase II trial	*Positive outcomes expected to lead to a pivotal Phase III trial*
Additional indication	Review and finalise selection of additional indication → **Indication associated with cognitive impairment** Phase II trial	*High unmet need focus with strong scientific rationale*

Actinogen Medical

Breakthrough results achieved in Phase 1 study

Phase 1 XanaHES study demonstrated statistically significant cognitive efficacy signal in multiple cognition domains based on Cogstate Cognitive Test Battery as early as 2 weeks[1]

Working memory (One Back Test)

Strongly statistically significant result



Visual attention (Identification Test)

Statistically significant result



Psychomotor function (Detection Test)

Good trend to a positive result



Treatment Group
Xanamem 30pts — Placebo 12 pts

Efficacy results achieved through sensitive and modern testing method which can now be utilised in future studies supported by increasing clinical adoption

Notes: All values are the means of observed data. p values were calculated with an ANCOVA (analysis of covariance) model using Baseline values as a covariate.
1. XanaHES Phase 1 clinical trial treated healthy elderly patients with 20mg Xanamem daily (n=30 active, n=12 placebo)

Bridging the positive Phase 1 cognition data to Alzheimer's patients

Targeting the first stage of Alzheimer's disease, measuring biomarkers



>US$13.7B

Target annual peak sales[1]

Actinogen Medical

Source: Alzheimer's Association, aibl study; Bio-Link Analysis

1. Sales in 2036. Case assumes: (1) Launch: US 2027, EU5, JP and ROW 2028; (2) Penetration: 30% of mild AD and MCI markets in 5 years, sustained for 6 years with patent extension; (3) Pricing: US – US$24/day gross (US$19/day net), ROW: 50% of US price.

XanaMIA Phase II trial has commenced

XanaMIA trial design is optimised for success

XanaMIA - Part A

(expected results in 1H CY22)

- **Healthy older subjects -** with normal cognition, ≥50 years of age (same as XanaHES trial)
- **Endpoints and testing criteria -** to leverage modern and highly sensitive cognition tests (Cogstate, iDSST)
- **Dose ranging -** at 5mg, 10mg Xanamem once daily

Dose ranging study to healthy elderly to **confirm minimum effective dose of Xanamem**

XanaMIA - Part B

(expected results in CY23)

- Targeting subjects with **mild cognitive impairment** due to Alzheimer's disease (using positive serum biomarkers)
- Bridging to patients with **modern and sensitive cognition tests** (Cogstate, iDSST) from Part A plus **biomarkers**
- Introducing other cognitive and functional endpoints that have been **accepted by regulators for later studies**

Phase II trial to **assess efficacy of Xanamem** in patients with MCI due to AD

Actinogen Medical

Review of data supports a low Xanamem dose

Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity at 5mg Xanamem doses and above

BASELINE

AFTER DOSE

5mg Xanamem | **10mg Xanamem** | **20mg Xanamem**



PET data demonstrates that Xanamem extensively binds to the 11β-HSD1 enzyme throughout the brain, with high post-treatment effects (absence of colour) after 7 days at all doses, including a 5mg Xanamem dose.

This is consistent with full hormonal pharmacodynamic activity seen with 10mg Xanamem in clinical trials.

XanaMIA Part A is seeking to confirm the minimum effective dose of Xanamem to use going forward.

Actinogen Medical

Note: Study population consisted of ~50% healthy subjects (cognitively normal) and ~50% with Alzheimer's disease. Subjects dosed for seven days.
Baseline: Mean of baseline scans of patients in that dose group; After dose: Mean of post-dosing (7 days) scans in that dose group.

Fragile X Phase II trial to commence in 2H CY21

Anxiety, sleep and behavioural problems in Fragile X syndrome are often associated with raised cortisol; Xanamem has the potential to improve symptoms

Unmet Medical Need	▪ Rare genetic condition, with life-long treatment required for patients (management is often complex) ▪ **There are no approved drugs to treat FXS**
Strategic Benefits	▪ **Fast-to-market** strategy ▪ Xanamem in FXS has been awarded **Rare Paediatric Disease Designation**
Data Generation	▪ **Positive Pre-IND FDA feedback** received for Actinogen's FXS program ▪ **Presents a significant potential upside with FXS-related conditions**, such as Autism Spectrum Disorder
Valuable Market Opportunity[1]	▪ Estimated **global market size of ~US$250M** ▪ FXS occurs in approx. 1 in 2500-4000 males and 1 in 7000-8000 females (averages to 1 / 4500)

Actinogen Medical

1. FSX market in 2026. GlobalData analyst report 2018. Projection for 7 major markets: US, France, Germany, Italy, Spain, UK, Japan

Significant value upside for Actinogen

Accelerate clinical development

Expand pipeline to show efficacy
- ❑ Expand pipeline with additional indications and clinical trials, providing multiple shots on goal

Enlarge clinical safety dataset
- ❑ Generate data to optimise potential partnership discussions

Optimise manufacturing
- ❑ Scale up and optimise manufacturing to prepare for commercially viable, large scale production

Potential commercial value

Big Pharma Partnership(s)
- ❑ Actively engaging with potential future partners
- ❑ High degree of interest worldwide in new Alzheimer's mechanisms

Tradeable PRV voucher
- ❑ Eligible through RPDD recently granted by FDA[2]
- ❑ Recently traded for US$100M-US$125M[3]

High Valuations in Alzheimer's Research
- ❑ Companies with a lead asset in phase II or III development for AD have valuations of at least US$350M[4]

1. US$1B based on the average disclosed values of 13 major global pharmaceutical deals (Oct 2018 to Mar 2020) considered to have material interest in AD (Source: Bio-Link analysis)
2. Eligible for a transferable (including by sale) Priority Review Voucher under Rare Paediatric Disease Designation from the FDA (if Xanamem is first registered in the US for FXS)
3. Potential to receive a Priority Review Voucher (PRV) upon approval in FXS – (Source: PRV value adapted from FDA website; Company press releases; priorityreviewvoucher.org)
4. Vivoryon Therapeutics, phase IIb AD lead asset (EURONEXT Amsterdam: 350 euro / ~US$500m); Athira Pharma, phase II AD lead asset (NASDAQ GS:US$370m); Cortexyme, phase III AD lead asset (NASDAQ GS:US$1.6B) and same drug in phase II for periodontal disease and Parkinson's disease; Cassava Sciences, AD lead asset phase III-ready (NASDAQ GS:US$2.7B). All companies' value primarily attributed to their lead AD asset. Market capitalisations as of approximately 02Aug2021.

Esteemed Advisory Boards

World-leading, premier academics involved in the development of Xanamem

Xanamem Clinical Advisory Board

Positions Xanamem at the forefront of drug development

Prof. Craig Ritchie
Chair

THE UNIVERSITY of EDINBURGH

Prof. Colin Masters *AO*

THE FLOREY INSTITUTE OF NEUROSCIENCE & MENTAL HEALTH

THE UNIVERSITY OF MELBOURNE

The Royal Melbourne Hospital

Prof. Jeffrey Cummings

Cleveland Clinic

Scientific Advisory Board

Combining deep understanding of endocrinology, 11β-HSD1 and drug discovery



Prof. Alan Boyd

BOYDS
Supporting development

Prof. Jonathan Seckl

THE UNIVERSITY of EDINBURGH

Prof. Brian Walker

Newcastle University

Prof. Scott Webster

THE UNIVERSITY of EDINBURGH

Actinogen Medical

Next steps and key catalysts

Actinogen has a strong balance sheet to execute its strategy and progress Xanamem clinical development

- **Clinical trials to commence in 2021***
  - XanaMIA Part A data expected in 1H2022
  - XanaFX data expected 2023
  - XanaMIA Part B data expected 2023
- **Pursue other high priority indications**
  - Leverage strong academic, grant collaborations
  - Start 3rd indication late 2021/early 2022
- **Expand team to pursue aggressive timelines**
- **Key publications and scientific presentations**

Actinogen Medical

*Note: Timing dependent on a number of external factors, including regulatory approvals.